Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced on Tuesday that its proprietary PDAOAI drug discovery and development platform will be featured during the Product & Engineering keynote at Qdrant Vector Space Day 2026. The event is scheduled for June 11 in San Francisco. Company executives will join Qdrant leadership to discuss how PDAOAI, operating on Qdrant infrastructure, has accelerated the development of two drug candidates from concept to investigational new drug (IND) filings in less than two years, significantly reducing the time and cost traditionally associated with pharmaceutical development.
The presentation will highlight several innovations underpinning the platform, including a proprietary “manifold folding” technique designed to improve semantic retrieval accuracy and reduce large language model hallucinations. Oncotelic also indexed approximately 28 million PubMed biomedical abstracts on Qdrant Cloud. The platform leverages advanced vector search technologies to support large-scale biomedical research and accelerate oncology drug discovery efforts, according to the company.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. In addition to its directly owned drug pipeline, the company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates in oncology and rare disease therapeutics. For more information about Oncotelic, visit the company’s newsroom at https://ibn.fm/OTLC.
